Analyst Consensus ?
ConsensusBuy34 ratings
Bullish2573.5%
Neutral926.5%
Bearish00.0%
Labcorp Holdings Inc. · LH · FY2026 Q2 · Calendar Q3 2026
Labcorp raises 2026 outlook as specialty testing drives Q2 growth
Labcorp's Q2 supports a constructive growth case: specialty testing, consumer services and acquisitions supported profitable growth, while the raised outlook indicates management sees momentum continuing. The case remains dependent on organic volume, reimbursement and margin execution.
Reported Before market openNYSEHealthcare
$25.55B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$4.99
Consensus $4.78
EPS surprise
+4.4%
Reported versus consensus
Reported revenue
$3.73B
Consensus $3.71B
Revenue surprise
+0.6%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+2.7%
Event window
SPY move
+1.7%
Same window
Abnormal move
+1.1%
Stock minus SPY
Volume
1.9×
Versus trailing sessions
Subsequent drift
+6.7%
Up to 20 sessions
LHSPY benchmark
Ask FN2 about LH FY2026 Q2
Transcript, numbers and history already loaded
Why did LH rise 2.7% after beating EPS estimates in FY2026 Q2?What changed in LH's guidance and outlook in FY2026 Q2?Give me the bull and bear case for LH after FY2026 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Versus the prior quarter, Labcorp delivered another solid period with stronger reported growth, launched or expanded access to specialty tests, raised full-year guidance again, and increased its repurchase authorization. The call also sharpened concerns around ACA/Medicaid policy, patient-pay mix and M&A discipline.
Guidance delta
Management raised full-year 2026 guidance to enterprise revenue growth of 5.4%-6.3% and adjusted EPS of $18.10-$18.55, with continued margin expansion.
Key takeaways
- Q2 revenue grew 6% and adjusted EPS rose 15% year over year, with enterprise margin up 70 basis points.
- Specialty testing, including oncology, neurology, autoimmune and women's health, delivered double-digit growth.
- ColoSense and NASHnext broadened the specialty-testing portfolio, while consumer growth remained double digit.
- Recent lab acquisitions expanded the regional footprint and the share-repurchase authorization increased to $1.4 billion.
Management priorities
- Expand specialty testing through ColoSense, NASHnext and other launches.
- Grow Labcorp OnDemand and the MyLabcorp app, including the Marker genetic panel.
- Deepen Epic Aura and pharma collaborations and continue targeted acquisitions.
- Advance consumer-focused and AI-enabled digital experiences.
Follow LH with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$311.54Previous close
$240Low
$314.32Average
$380High
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Sep 23, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Truist Securities | Buy | Buy | Maintain | Sep 21, 2026 |
| UBS | Buy | Buy | Maintain | Sep 11, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Sep 11, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Aug 4, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Aug 3, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Jul 31, 2026 |
| Baird | Outperform | Outperform | Maintain | Jul 13, 2026 |
| B of A Securities | Buy | Buy | Maintain | Jul 13, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Apr 8, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Oct 17, 2025 |
| Citigroup | Buy | Neutral | Upgrade | Mar 4, 2025 |
| Jefferies | Buy | Buy | Maintain | Feb 6, 2025 |
| HSBC | Buy | Hold | Upgrade | Oct 30, 2024 |
| Deutsche Bank | Hold | Hold | Maintain | Aug 2, 2024 |
| Argus Research | Buy | Hold | Upgrade | Mar 25, 2024 |
| Wells Fargo | Overweight | Overweight | Maintain | Aug 14, 2023 |
| Credit Suisse | Outperform | Outperform | Maintain | Aug 2, 2023 |
| Wolfe Research | Outperform | Peer Perform | Upgrade | Jul 13, 2020 |
| SunTrust Robinson Humphrey | Buy | Buy | Maintain | May 21, 2020 |
| KeyBanc | Overweight | Overweight | Maintain | Mar 30, 2020 |
| Bank of America | Neutral | Underperform | Upgrade | Jul 16, 2019 |
| Canaccord Genuity | Hold | Hold | Maintain | May 2, 2019 |
| Goldman Sachs | Buy | Conviction Buy | Downgrade | Nov 30, 2018 |
| Argus | Hold | Buy | Downgrade | Oct 30, 2018 |
| JMP Securities | Outperform | Market Outperform | Maintain | Mar 27, 2015 |
| Maxim Group | Buy | Buy | Maintain | Mar 24, 2015 |
| PiperJaffray | Overweight | Neutral | Upgrade | Feb 23, 2015 |
| Raymond James | Outperform | Underperform | Upgrade | Jan 2, 2015 |
| FBR Capital | Market Perform | Market Perform | Maintain | Oct 28, 2014 |
| William Blair | Outperform | Market Perform | Upgrade | Jul 17, 2014 |
| Cantor Fitzgerald | Buy | Buy | Maintain | May 9, 2014 |
| ISI Group | Neutral | Neutral | Maintain | Nov 19, 2013 |
| Craig-Hallum | Buy | Buy | Maintain | Aug 28, 2013 |
| Oppenheimer | Perform | Perform | Maintain | Jan 28, 2013 |
Named analyst price targets
Upside is calculated against the persisted previous close $311.54. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Truist Financial | David MacDonald | $365 | $320.71 | +17.2% | Sep 21, 2026 |
| UBS | Kevin Caliendo | $380 | $307.42 | +22.0% | Sep 11, 2026 |
| Barclays | Analyst unavailable | $330 | $306.96 | +5.9% | Sep 11, 2026 |
| Mizuho Securities | Ann Hynes | $355 | $319.17 | +14.0% | Aug 10, 2026 |
| Morgan Stanley | Analyst unavailable | $338 | $308.64 | +8.5% | Jul 31, 2026 |
| Deutsche Bank | Analyst unavailable | $306 | $308.7 | -1.8% | Jul 31, 2026 |
| Robert W. Baird | Analyst unavailable | $352 | $315.53 | +13.0% | Jul 31, 2026 |
| Barclays | Analyst unavailable | $320 | $315.82 | +2.7% | Jul 30, 2026 |
| Robert W. Baird | Eric Coldwell | $334 | $255.97 | +7.2% | May 1, 2026 |
| Evercore ISI | Analyst unavailable | $300 | $274.72 | -3.7% | Apr 8, 2026 |
| Piper Sandler | David Westenberg | $300 | $285.3 | -3.7% | Feb 24, 2026 |
| Robert W. Baird | Analyst unavailable | $326 | $276.67 | +4.6% | Feb 18, 2026 |
| Robert W. Baird | Analyst unavailable | $313 | $259.18 | +0.5% | Jan 14, 2026 |
| UBS | Kevin Caliendo | $320 | $253.74 | +2.7% | Oct 29, 2025 |
| Robert W. Baird | Analyst unavailable | $304 | $259.69 | -2.4% | Oct 29, 2025 |
| Leerink Partners | Michael Cherny | $342 | $261.62 | +9.8% | Oct 28, 2025 |
| UBS | Analyst unavailable | $325 | $285.93 | +4.3% | Oct 17, 2025 |
| Mizuho Securities | Ann Hynes | $320 | $283.71 | +2.7% | Oct 17, 2025 |
| Truist Financial | Analyst unavailable | $320 | $278.42 | +2.7% | Oct 14, 2025 |
| Evercore ISI | Analyst unavailable | $305 | $279.44 | -2.1% | Oct 3, 2025 |
| Barclays | Analyst unavailable | $290 | $279.06 | -6.9% | Oct 2, 2025 |
| Robert W. Baird | Analyst unavailable | $311 | $276.11 | -0.2% | Aug 25, 2025 |
| UBS | Kevin Caliendo | $305 | $264.96 | -2.1% | Jul 25, 2025 |
| Barclays | Analyst unavailable | $275 | $258.7 | -11.7% | Jun 25, 2025 |
| Barclays | Luke Sergott | $271 | $247.86 | -13.0% | Feb 3, 2025 |
| Evercore ISI | Elizabeth Anderson | $240 | $224.72 | -23.0% | Sep 24, 2024 |
| Jefferies | Brian Tanquilut | $265 | $222.22 | -14.9% | Sep 23, 2024 |
| Bank of America Securities | Michael Ryskin | $260 | $236 | -16.5% | Aug 5, 2024 |
| Robert W. Baird | Eric Coldwell | $277 | $235.67 | -11.1% | Aug 2, 2024 |
| Argus Research | David Toung | $250 | $212.5 | -19.8% | Mar 25, 2024 |
| Morgan Stanley | Analyst unavailable | $303 | $241.42 | -2.7% | Jan 6, 2023 |
| Credit Suisse | Analyst unavailable | $305 | $238 | -2.1% | Nov 23, 2022 |
| Mizuho Securities | Analyst unavailable | $296 | $254.72 | -5.0% | Jul 29, 2022 |
| Deutsche Bank | Analyst unavailable | $265 | $245.45 | -14.9% | May 3, 2022 |
| Credit Suisse | Analyst unavailable | $312 | $240.28 | +0.1% | May 2, 2022 |
| Wells Fargo | Analyst unavailable | $315 | $266.12 | +1.1% | Apr 25, 2022 |
| Bank of America Securities | Derik de Bruin | $370 | $276.26 | +18.8% | Feb 11, 2022 |
| Deutsche Bank | Pito Chickering | $294 | $270.08 | -5.6% | Jan 28, 2022 |
| Truist Financial | David S Macdonald | $350 | $296.15 | +12.3% | Jul 30, 2021 |
| Argus Research | Jasper Hellweg | $295 | $269.61 | -5.3% | May 20, 2021 |
Track every rating change on LH the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationLabcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
Historical context
All LH earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| COO The Cooper Companies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +2.7% | -14.7% | CooperCompanies beats expectations as inventory reduction weighs on vision revenue |
| MDT Medtronic plc | FY2027 Q1 · Calendar Q3 2026 | +4.3% | +1.5% | Medtronic raises FY27 outlook as growth broadens across platforms |
| A Agilent Technologies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +8.7% | +1.7% | Agilent raises outlook after Q3 beat; Ignite drives margin gains |
Latest beats and misses
Who reports nextBeat on EPS
- AZOFY2026 Q4 · September 22, 2026+3.6% EPS+3.3% move
- FPSFY2026 Q4 · September 15, 2026+4.3% EPS+9.5% move
- TCOMFY2026 Q2 · September 15, 2026+22.3% EPS+3.0% move
- KRFY2026 Q2 · September 11, 2026+2.8% EPS+2.7% move
- ADBEFY2026 Q3 · September 10, 2026+0.8% EPS+1.4% move
- ORCLFY2027 Q1 · September 10, 2026+10.3% EPS-1.7% move
Get the LH recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-07-30T22:18:45.910682+00:00
- FN2 earnings calendar · 2026-09-04T01:23:15.205020+00:00
- Polygon adjusted daily market bars · 2026-09-23T09:30:54.648316+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-09-23T09:30:54.645170+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-09-23. For educational purposes only; not investment advice.